Gao Y H, Wang Y X, Li J, He M, Qi Z, Qiu R, Qiao X Y
Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China (Currently address: Department of Medical Oncology, the Second Central Hospital of Baoding, Zhuozhou 072750, China).
Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Zhonghua Zhong Liu Za Zhi. 2017 Sep 23;39(9):683-688. doi: 10.3760/cma.j.issn.0253-3766.2017.09.009.
To investigate the postoperative prognosis and the related factors of patients with stage pT2N0-1M0 of thoracic esophageal carcinoma(EC). From 2008 to 2011, clinical data of 275 cases with stage pT2N0-1M0 of thoracic EC treated by esophagectomy were enrolled. These cases includ 180 male and 95 female. Among them, 32 cases were upper thoracic EC, 186 cases were middle thoracic EC and 57 cases were lower thoracic EC. Alternatively, 205 cases were stage pN0, 70 cases were stage pN1. 155 cases received esophagectomy alone and 120 cases received esophagectomy and postoperative adjuvant therapy. The end of follow-up time was on September 30th, 2014. The 1-, 3-, 5-year overall survival (OS) rates were 91.6%, 70.2% and 63.7%, respectively. The 1- 3-, 5-year progression-free survival (PFS) rates were 83.9%, 64.0% and 60.0%, respectively. The result of univariate analysis showed that the depth of tumor invasion, pathological type, pN stage and number of metastatic lymph nodes were significantly associated with OS (all of <0.05). Moreover, the gender, the depth of tumor invasion, pathological type, pN stage and number of metastatic lymph nodes were significantly associated with PFS (all of <0.05). Cox multivariate analysis showed that the location of primary tumor and pN stage were the independent factors of OS (both <0.05). The gender, pN stage and postoperative adjuvant therapy were the independent factors of PFS (all of <0.05). Among the patients with pT2N0~1M0 stage of thoracic EC, patients with upper thoracic EC or pN1 stage have poorer postoperative prognosis compared with others, and postoperative adjuvant treatment is recommended for these patients.
探讨胸段食管癌（EC）pT2N0-1M0期患者的术后预后及相关因素。收集2008年至2011年275例行食管癌切除术的胸段EC患者pT2N0-1M0期的临床资料。其中男性180例，女性95例。胸段上段EC 32例，胸段中段EC 186例，胸段下段EC 57例。pN0期205例，pN1期70例。单纯行食管癌切除术155例，行食管癌切除术后辅助治疗120例。随访截止时间为2014年9月30日。1年、3年、5年总生存率（OS）分别为91.6%、70.2%和63.7%。1年、3年、5年无进展生存率（PFS）分别为83.9%、64.0%和60.0%。单因素分析结果显示，肿瘤浸润深度、病理类型、pN分期及转移淋巴结数量与OS均显著相关（均P<0.05）。此外，性别、肿瘤浸润深度、病理类型、pN分期及转移淋巴结数量与PFS均显著相关（均P<0.05）。Cox多因素分析显示，原发肿瘤部位和pN分期是OS的独立影响因素（均P<0.05）。性别、pN分期及术后辅助治疗是PFS的独立影响因素（均P<0.05）。在胸段EC患者pT2N0~1M0期，胸段上段EC或pN1期患者术后预后较其他患者差，建议对这些患者行术后辅助治疗。
Zotero 插件